BCTX
BriaCell Therapeutics Corp.
NASDAQ · Healthcare · Biotechnology · CA
$3.57
+1.13%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
Market Cap
$31.06M
MomentumView details →
1D Return
+1.13%
YTD Return
−50.98%
RSI (14)
46.5
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
Market Cap
$31.06M
RSI (14)
46.5
MomentumView details →
1D Return
+1.13%
YTD Return
−50.98%
SummaryUpdated Apr 1, 2026
BriaCell Therapeutics Corp. (NASDAQ:BCTX) is a Canadian immuno-oncology biotechnology company founded in 2012 and headquartered in West Vancouver, Canada. The company went public on March 14, 2012, and focuses on developing innovative immunotherapies specifically designed to treat various forms of cancer. BriaCell operates as a clinical-stage biopharmaceutical company with no current commercial products, dedicating its resources to advancing novel cancer treatment approaches through its proprietary immunotherapy platform.
Similar companies
Latest newsMore news →